Trazodone (Desyrel): How It Works, Uses for Sleep and Depression, Dosage, Side Effects and Complete 2026 Guide
Trazodone is one of the most prescribed yet least-discussed mental health medications in the United States — ranking 16th on the GoodRx list of most-prescribed drugs nationally, and October's Mental Health Awareness Month data from BuzzRx confirms that females aged 30–39 fill the most mental health prescriptions nationwide. Sold under the brand name Desyrel and widely available as an inexpensive generic, trazodone occupies a unique clinical position that almost no other psychiatric drug holds: it is FDA-approved for major depression at higher doses and simultaneously one of the most widely prescribed off-label sleep medications in the country at lower doses.
This dose-dependent dual function — sedating hypnotic at 25–100mg at night, antidepressant at 150–600mg per day — explains both its clinical versatility and one of the most important practical facts about trazodone that patients frequently do not know: the dose completely changes what the drug is doing. A patient taking 50mg at bedtime for insomnia is not receiving antidepressant therapy. A patient taking 300mg daily for depression is not primarily using it as a sleep drug. Understanding this dose-dependence is the foundation of using trazodone correctly.
Trazodone also has an important practical advantage that drives its widespread use: it is not a controlled substance. Unlike zopiclone, zolpidem (Ambien), and benzodiazepines — all Schedule IV or equivalent controlled substances carrying significant abuse and dependence concerns — trazodone can be prescribed without the prescribing restrictions that apply to controlled hypnotics. For patients, caregivers, and prescribers concerned about dependence, trazodone's non-controlled status is often the deciding factor.
This complete 2026 guide covers trazodone's unique SARI (serotonin antagonist and reuptake inhibitor) mechanism, how the two doses do different things, the correct dosing for sleep versus depression, why it should be taken on an empty stomach when used for insomnia, the priapism warning (rare but serious), the MAOI absolute contraindication and serotonin syndrome, CYP3A4 interactions, why the AASM recommends caution for chronic insomnia, and how trazodone compares to SSRIs, mirtazapine, and zopiclone.
MedlinePlus provides comprehensive trazodone patient information at: https://medlineplus.gov/druginfo/meds/a681038.html
How Trazodone Works — The SARI Mechanism
Trazodone belongs to a unique pharmacological class called SARI — Serotonin Antagonist and Reuptake Inhibitor. This dual mechanism explains both its sleep-promoting and antidepressant properties, and why the dose matters so much:
Action 1 — 5-HT2A receptor antagonism (dominant at low doses):
Trazodone blocks 5-HT2A serotonin receptors. This antagonism is the primary mechanism at low doses (25–100mg) and produces:
Sedation — 5-HT2A blockade in arousal circuits reduces wakefulness signalling
Improved sleep architecture — 5-HT2A antagonism increases slow-wave (deep) sleep and normalises REM sleep, unlike many hypnotics that suppress REM; trazodone's sleep quality effect is more physiologically similar to natural sleep than GABA-A modulators (zopiclone, zolpidem)
Reduced anxiety at low doses — 5-HT2A blockade has anxiolytic properties
Fewer sexual side effects — 5-HT2A antagonism actually counteracts the sexual dysfunction caused by serotonin reuptake inhibition, which is why trazodone has fewer sexual side effects than SSRIs
Action 2 — Serotonin reuptake inhibition (dominant at higher doses):
At higher doses (above 150mg), trazodone's serotonin reuptake inhibition becomes clinically significant — increasing synaptic serotonin in the prefrontal cortex and limbic system, producing antidepressant effects. This is why:
25–100mg → primarily sedating/sleep-promoting; minimal antidepressant effect
150mg and above → antidepressant effect emerges alongside continued sedation
Action 3 — Histamine H1 receptor antagonism:
Trazodone also blocks histamine H1 receptors — contributing an additional sedative effect. This is similar to the mechanism of the antihistamine diphenhydramine (Benadryl) but through a different receptor profile and without the significant anticholinergic (dry mouth, urinary retention, confusion) effects of antihistamines.
Action 4 — Alpha-1 adrenergic receptor antagonism:
Trazodone blocks alpha-1 adrenergic receptors — producing vasodilation and blood pressure lowering. This contributes to:
Orthostatic hypotension (dizziness when standing up quickly) — particularly important in elderly patients
The priapism mechanism — alpha-1 blockade in penile vasculature causes engorgement (see safety section)
Why trazodone is different from SSRIs:
SSRIs (sertraline, escitalopram, fluoxetine) work exclusively through serotonin reuptake inhibition — they block SERT and raise synaptic serotonin. They have no 5-HT2A antagonism, histamine blocking, or alpha-1 effects. This is why SSRIs commonly cause insomnia and sexual dysfunction — effects that trazodone's additional mechanisms actually counteract. Trazodone is often added to an SSRI specifically to treat SSRI-induced insomnia and sexual dysfunction.
FDA-Approved Indication and Major Off-Label Uses
FDA-approved indication:
Major Depressive Disorder (MDD) — the only FDA-approved indication for trazodone. At antidepressant doses (150–400mg daily, up to 600mg in hospitalised patients), trazodone has been shown to be effective for MDD in clinical trials. It is no longer a first-line antidepressant in most guidelines — SSRIs and SNRIs have largely superseded it for depression — but it retains an important role when:
Depression is accompanied by significant insomnia (the sedation is an advantage rather than a side effect)
SSRIs have caused intolerable sexual dysfunction and switching to trazodone is appropriate
Elderly patients need an antidepressant with less cardiac toxicity than tricyclics and less activation than SSRIs
Off-label use 1 — Insomnia (most common use in 2026):
Trazodone at 25–100mg at bedtime is the most prescribed off-label sleep medication in the USA. It is particularly popular because:
It is not a controlled substance — no DEA scheduling restrictions on prescribing
Lower dependence risk than zopiclone, zolpidem, and benzodiazepines
Does not suppress REM sleep — superior sleep architecture compared to most hypnotics
Low cost — widely available as a cheap generic
However — the 2017 AASM guideline on medications for chronic insomnia in adults does NOT recommend trazodone as a first-line or second-line treatment for primary insomnia. The guideline states: "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia disorder." Trazodone is most appropriately used when insomnia accompanies depression or anxiety (treating both simultaneously), or as a short-term bridge when first-line options have failed.
Off-label use 2 — Anxiety disorders:
Trazodone's 5-HT2A antagonism and sedating properties provide modest anxiolytic benefit — it is used in generalised anxiety disorder and PTSD, particularly for the hyperarousal and sleep disturbance components.
Off-label use 3 — PTSD nightmares and hyperarousal:
A specific off-label use with some evidence — trazodone reduces the frequency of nightmares and improves sleep consolidation in PTSD patients; used in addition to or instead of prazosin (the more established off-label PTSD sleep treatment).
Off-label use 4 — Augmentation of SSRI treatment:
Frequently added to an existing SSRI prescription to treat SSRI-induced insomnia, SSRI-induced sexual dysfunction, or insufficient antidepressant response. The trazodone augmentation strategy is one of the most common combination prescribing patterns in primary care psychiatry.
Dosage — Complete Guide
The dose-dependence of trazodone's effects makes correct dosing critically important:
Indication | Starting Dose | Titration | Typical Therapeutic Dose | Maximum Dose |
Insomnia (off-label) | 25–50mg at bedtime | Increase by 50mg increments if needed | 50–100mg at bedtime | 200mg at bedtime |
Major depression | 75mg daily (in divided doses) | Increase by 50mg every 3–4 days | 150–400mg/day | 600mg/day (inpatients) |
Anxiety / PTSD augmentation (off-label) | 25–50mg at bedtime | Titrate slowly | 50–150mg/day | 200mg/day |
SSRI augmentation for insomnia | 25–50mg at bedtime | Stay at lowest effective dose | 50–100mg at bedtime | 150mg at bedtime |
Critical dosing timing rules:
For insomnia: take on an EMPTY STOMACH 30–60 minutes before bed. Food delays trazodone absorption by 1–2 hours when used for insomnia — significantly impairing the hypnotic onset. This is the opposite of most medications: for sleep use, empty stomach is best.
For depression: take with food to reduce GI side effects (nausea). Larger portion of the daily dose is typically given at bedtime to minimise daytime sedation.
Dose timing — morning vs bedtime:
Most patients take trazodone at bedtime — the sedation is an advantage for sleep and depression-with-insomnia. However, a small proportion of patients find trazodone stimulating rather than sedating — for these individuals, morning dosing may be more appropriate. This stimulating response is uncommon but worth knowing about if a patient reports insomnia getting worse on trazodone.
Never increase the dose faster than prescribed: the titration schedule exists to minimise dizziness, orthostatic hypotension, and daytime sedation.
Side Effects — Complete and Honest Profile
Side effects that typically resolve with time or dose adjustment:
Drowsiness and sedation — most common; desired for insomnia use; problematic for daytime functioning in depression treatment; usually improves as the body adapts
Dizziness and lightheadedness — particularly on standing (orthostatic hypotension from alpha-1 blockade); stand up slowly; more common in elderly
Dry mouth — mild; less than tricyclic antidepressants
Blurred vision — usually transient
Nausea — reduced by taking with food (for depression dosing)
Next-day grogginess — the most common patient complaint; particularly at doses above 100mg; reduced by taking the dose earlier in the evening
Headache — usually transient
Weight changes — trazodone has less weight gain effect than mirtazapine or TCAs; broadly weight-neutral
Serious side effects requiring immediate medical attention:
Priapism — the most clinically distinctive trazodone risk:
Trazodone is associated with priapism — a prolonged, painful erection not related to sexual stimulation — at a rate of approximately 1 in 6,000 male patients. The mechanism is alpha-1 adrenergic blockade in the corpora cavernosa of the penis — the same mechanism as the drug's blood pressure effects but localised to penile vasculature.
Priapism is a medical emergency. An erection lasting more than 4 hours causes ischaemic damage to penile erectile tissue. Without treatment within 4–6 hours, permanent erectile dysfunction can result. Emergency treatment involves aspiration of blood from the corpora cavernosa and/or injection of a vasoconstrictive agent.
Who is most at risk: younger males, sickle cell disease patients, patients on other alpha-1 blocking drugs (tamsulosin, prazosin, doxazosin). Trazodone should be used with particular caution in males with risk factors for priapism.
Men taking trazodone should be explicitly warned about this risk at initiation. Report any prolonged erection immediately to the emergency department — do not wait.
Serotonin syndrome:
As a serotonergic drug, trazodone can contribute to serotonin syndrome — particularly when combined with other serotonergic medications. Risk is highest when combined with MAOIs (absolute contraindication — see below), other SSRIs/SNRIs at higher doses, tramadol, triptans (sumatriptan), St John's Wort, or linezolid. Symptoms: agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, tremor, diarrhoea, high temperature, muscle rigidity. Seek emergency care immediately.
Cardiac arrhythmia and QTc prolongation:
Trazodone can prolong the QT interval — particularly at higher antidepressant doses. Risk increases with electrolyte disturbances (low potassium or magnesium), concurrent QTc-prolonging drugs, or pre-existing cardiac conditions. Caution in patients with cardiac disease.
Suicidal ideation — the antidepressant class black box warning:
All antidepressants including trazodone carry an FDA black box warning for increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 25 during initial treatment. This applies to trazodone at antidepressant doses. Monitor closely during the first 4 weeks and after any dose change in younger patients. Report any worsening suicidal thoughts immediately.
The MAOI Absolute Contraindication
Trazodone must never be combined with monoamine oxidase inhibitors (MAOIs) — phenelzine, tranylcypromine, isocarboxazid, selegiline, or linezolid (which has MAOI properties). The combination produces serotonin syndrome — potentially fatal. The required washout period is 14 days after stopping a MAOI before starting trazodone, and 14 days after stopping trazodone before starting a MAOI.
Critical Drug Interactions
Drug / Class | Interaction | Risk | Action |
MAOIs | Serotonin syndrome | Life-threatening | Absolute contraindication — 14-day washout both ways |
CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, fluconazole, grapefruit juice) | Raise trazodone blood levels → increased side effects | Moderate-High | Use with caution; consider dose reduction; monitor for sedation and QTc |
CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) | Lower trazodone levels → reduced efficacy | Moderate | May need dose increase; monitor clinical response |
Other SSRIs/SNRIs | Additive serotonergic effect | Low-Moderate | Use at low doses; monitor for serotonin syndrome signs |
Alcohol | Additive CNS depression | Moderate | Avoid alcohol while taking trazodone |
Other CNS depressants (opioids, benzodiazepines, zopiclone) | Additive sedation | Moderate | Caution; respiratory depression risk at high doses |
Alpha-1 blockers (tamsulosin, doxazosin) | Additive hypotension; increased priapism risk | Moderate | Use with caution; monitor BP; priapism risk in males |
Digoxin | Trazodone may raise digoxin levels | Moderate | Monitor digoxin levels |
Warfarin | May alter INR | Mild | Monitor INR when starting, stopping, or changing trazodone dose |
Trazodone vs Alternatives — When to Choose It
Feature | Trazodone | Zopiclone (sleep) | Sertraline (depression) | Mirtazapine |
FDA-approved for depression | Yes | No | Yes | Yes |
FDA-approved for insomnia | No — off-label | No — not FDA approved | No | No |
Controlled substance | No — significant advantage | Equivalent to Schedule IV | No | No |
Dependence risk | Low | Moderate-High | Very low | Very low |
Sexual side effects | Low — advantage | N/A | Common (30–40%) | Low |
Weight gain | Low | Minimal | Low-mild | Significant |
Sleep architecture | Improves SWS, preserves REM | Reduces SWS and REM | Variable | Improves |
Sedation | Yes — day and night | Night only (short) | Low | Yes |
Priapism risk | Yes (1:6,000 males) | No | No | No |
QTc concern | Yes — at higher doses | Less | Low | Mild |
Best for | Depression with insomnia; off-label sleep; SSRI augmentation; avoidance of controlled substances | Short-term pure insomnia (2–4 weeks) | Depression; anxiety; OCD; PTSD | Depression with insomnia and poor appetite |
For our complete guide on sertraline — the most widely prescribed SSRI; trazodone is frequently added to sertraline to manage SSRI-induced insomnia and sexual dysfunction: [Sertraline (Zoloft): Complete SSRI Guide 2026]
For our guide on zopiclone — the controlled sleep medication to which trazodone is often preferred specifically because it is not a controlled substance: [Zopiclone for Insomnia: Complete 2026 Sleep Guide]
For our guide on anxiety — trazodone is used off-label for anxiety and PTSD hyperarousal; understanding the anxiety treatment landscape: [Anxiety Disorders: Types, Symptoms, Causes and Treatment Guide]
The NAMI trazodone patient resource is available at: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Trazodone
A comprehensive NIH PMC systematic review of trazodone for insomnia is available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413705/
Frequently Asked Questions
What is trazodone used for and how does it work differently at different doses?
Trazodone is FDA-approved for major depression and widely used off-label for insomnia. It belongs to the SARI class — Serotonin Antagonist and Reuptake Inhibitor — which means it works through two mechanisms. At low doses (25 to 100mg at bedtime), 5-HT2A receptor antagonism and histamine H1 blockade dominate, producing sedation and improved sleep quality without significant antidepressant effect. At higher doses (150mg and above daily), serotonin reuptake inhibition becomes clinically significant, producing antidepressant effects alongside sedation. The dose completely determines what the drug is primarily doing — a 50mg bedtime dose for sleep is pharmacologically very different from 300mg daily for depression.
Is trazodone a controlled substance?
No — trazodone is not a controlled substance under the DEA Controlled Substances Act. This is one of its most clinically significant practical advantages over other sleep medications. Zopiclone, zolpidem (Ambien), and benzodiazepines are all Schedule IV controlled substances with prescribing restrictions, abuse potential, and physical dependence liability. Trazodone can be prescribed without DEA scheduling restrictions and carries substantially lower dependence risk, making it the preferred choice for many prescribers concerned about dependence — particularly in patients with a history of substance use disorder.
What is priapism and how likely is it with trazodone?
Priapism is a prolonged, painful erection not caused by sexual stimulation. Trazodone's alpha-1 adrenergic blocking effect in penile vasculature can cause blood to pool in the corpora cavernosa, producing engorgement. It occurs in approximately 1 in 6,000 male patients — rare but clinically important. An erection lasting more than 4 hours causes ischaemic damage to erectile tissue; without emergency treatment within 4 to 6 hours, permanent erectile dysfunction can result. Men taking trazodone should go to the emergency department immediately for any prolonged erection regardless of the time. Risk is higher in young males, sickle cell disease patients, and those on other alpha-1 blocking drugs such as tamsulosin. Women are not at risk of priapism but should be aware of clitoral engorgement as a related rare effect.
Why should trazodone be taken on an empty stomach when used for sleep?
When trazodone is used for insomnia, it should be taken 30 to 60 minutes before bed on an empty stomach. Food significantly delays trazodone absorption by 1 to 2 hours — meaning a dose taken with food at 10pm may not reach sedating peak levels until midnight or later, missing the desired sleep window. Taking it without food maximises the speed of onset for the hypnotic effect. This is the opposite of the recommendation for depression dosing — when trazodone is taken in divided daily doses for depression, taking with food reduces nausea.
What is the difference between trazodone and zopiclone for sleep?
Both are used for insomnia but through entirely different mechanisms and with key practical differences. Trazodone works via 5-HT2A antagonism and histamine blocking, improves slow-wave sleep and preserves REM sleep, is not a controlled substance, and carries low dependence risk but does carry priapism risk in males. Zopiclone works via GABA-A receptor potentiation (similar to benzodiazepines), is associated with higher dependence liability, requires only 2 to 4 weeks of use maximum, and produces the characteristic bitter metallic taste. Trazodone can be used longer-term with less concern about physiological dependence. For patients who need a sleep medication without controlled substance restrictions, or for those on SSRIs needing both antidepressant augmentation and sleep improvement, trazodone is often preferred.
Comments